Teva filed an EU court appeal this month to contest a fine of 60.5 million euros ($73 million) imposed on it and Cephalon for delaying the market entry of a cheaper drug to treat sleep disorders.In November, the European Commission wrapped up a probe into a 2005 agreement between Teva and US peer